Claims
- 1. A composition of matter for the transdermal administration of ST-1435, the composition comprising, in combination, an amount of ST-1435 to deliver at least 20 .mu.g/day of ST-1435 and a skin permeation-enhancing amount of a suitable permeation enhancer, the permeation enhancer being selected from the group consisting of C.sub.2-4 alcohols, polyethylene glycol monolaurate, polyethylene glycol-3-lauramide, dimethyl lauramide, esters of fatty acids having from 10 to 20 carbon atoms, diglycerides of fatty acids, triglycerides of fatty acids, monoglycerides and mixtures of monoglycerides of fatty acids having a total monoesters content of at least 51% where the fatty acids have from 10 to 20 carbon atoms.
- 2. A composition according to claim 1 wherein the permeation enhancer is a monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51%.
- 3. A composition according to claim 2 wherein the permeation enhancer is glycerol monooleate, glycerol monolinoleate, or glycerol monolaurate.
- 4. A method for the transdermal administration of ST-1435, which method comprises:
- (a) administering the ST-1435 at a rate of at least 20 .mu.g/day to an area of skin, the area being of from about 1 cm.sup.2 to about 50 cm.sup.2 ; and
- (b) simultaneously administering a suitable permeation enhancer to the area of skin at a rate which is sufficient to substantially increase the permeability of the area to the ST-1435, the permeation enhancer being selected from the group consisting of C.sub.2-4 alcohols, polyethylene glycol monolaurate, polyethylene glycol-3-lauramide, dimethyl lauramide, esters of fatty acids having from 10 to 20 carbon atoms, diglycerides of fatty acids, triglycerides of fatty acids, monoglycerides and mixtures of monoglycerides of fatty acids having a total monoesters content of at least 51% where the fatty acids have from 10 to 20 carbon atoms.
- 5. A method according to claim 4 wherein the permeation enhancer is a monoglyceride or mixture of monoglycerides of fatty acid with a total monoesters content of at least 51%.
- 6. A method according to claim 5 wherein the permeation enhancer is glycerol monooleate, glycerol monolinoleate or glycerol monolaurate.
- 7. A method for providing contraception to a woman, which method comprises:
- (a) administering ST-1435 at a rate of at least 20 .mu.g/day to an area of the woman's skin, the area being of from about 1 cm.sup.2 to about 50 cm.sup.2 ; and
- (b) simultaneously administering a suitable permeation enhancer to the area of skin at a rate which is sufficient to substantially increase the permeability of the area to the ST-1435, the permeation enhancer being selected from the group consisting of C.sub.2-4 alcohols, polyethylene glycol monolaurate, polyethylene glycol-3-lauramide, dimethyl lauramide, esters of fatty acids having from 10 to 20 carbon atoms, diglycerides of fatty acids, triglycerides of fatty acids, monoglycerides and mixtures of monoglycerides of fatty acids having a total monoesters content of at least 51% where the fatty acids have from 10 to 20 carbon atoms.
- 8. A method according to claim 7 wherein the permeation enhancer is a monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51%.
- 9. A method according to claim 8 wherein the permeation enhancer is glycerol monooleate, glycerol monolinoleate or glycerol monolaurate.
- 10. A device for the transdermal administration of ST-1435, which device is of a size of from about 1 cm.sup.2 to about 50 cm.sup.2 and comprises:
- (a) a reservoir comprising a matrix containing a contraceptively effective amount of ST-1435 to deliver at least 20 .mu.g/day and a skin permeation-enhancing amount of a suitable permeation enhancer, the permeation enhancer being selected from the group consisting of C.sub.2-4 alcohols, polyethylene glycol monolaurate, polyethylene glycol-3-lauramide, dimethyl lauramide, esters of fatty acids having from 10 to 20 carbon atoms, diglycerides of fatty acids, triglycerides of fatty acids, monoglycerides and mixtures of monoglycerides of fatty acids having a total monoesters content of at least 51% where the fatty acids have from 10 to 20 carbon atoms;
- (b) a backing on the skin-distal surface of the reservoir; and
- (c) means for maintaining the reservoir in ST-1435- and permeation enhancer-transmitting relation with the skin.
- 11. A device according to claim 10 wherein the permeation enhancer is a monoglyceride or mixture of monoglycerides of fatty acids with a total monoesters content of at least 51%.
- 12. A device according to claim 11 wherein the permeation enhancer is glycerol monooleate, glycerol monolinoleate or glycerol monolaurate.
- 13. A device according to claim 10 wherein the permeation enhancer is glycerol monooleate and the matrix comprises ethylene vinyl acetate copolymer having from about 9 to 60% vinyl acetate.
- 14. A device according to claim 13 wherein the means for maintaining the reservoir in relation with the skin comprises an in-line adhesive layer on the skin-proximal surface of the reservoir.
Parent Case Info
This application is a continuation of application Ser. No. 07/858,208, filed Mar. 26, 1992, now abandoned which is a continuation-in-part of application Ser. No. 07/848,578, filed Mar. 9, 1992, now a U.S. Pat. No. 5,198,223 which is a continuation-in-part of application Ser. No. 07/605,726, filed Oct. 29, 1990, now U.S. Pat. No. 5,122,382.
US Referenced Citations (23)
Foreign Referenced Citations (1)
Number |
Date |
Country |
1532388 |
Oct 1988 |
AUX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
858208 |
Mar 1992 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
848578 |
Mar 1992 |
|
Parent |
605726 |
Oct 1990 |
|